Japanese Major Depressive Disorder (MDD) Market
Japan Major Depressive Disorder (MDD) Market Forecast and Opportunities 2020-2030: Increasing Awareness and Decreasing Stigma of Mental Health Disorders
September 16, 2024 06:15 ET | Research and Markets
Dublin, Sept. 16, 2024 (GLOBE NEWSWIRE) -- The "Japan Major Depressive Disorder (MDD) Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ...
22157.jpg
Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University, Johnson & Johnson, Shire Pharmaceuticals, Pfizer, Lykos, and UCB
September 13, 2024 06:55 ET | Research and Markets
Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Psychedelic Therapeutics" report has been added to ResearchAndMarkets.com's offering.This report provides a review of global...
PharmAla Biotech Logo 800 x 422.png
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
September 11, 2024 08:55 ET | PharmAla Biotech
PharmAla completes sales agreement with Johns Hopkins Medicine, terminates contract with Red Light Holland, to present novel molecule at conference.
PharmAla Biotech Logo 800 x 422.png
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024 09:07 ET | PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
NEW ATAI-Logo_Primary.png
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
August 13, 2024 07:00 ET | atai Life Sciences
VLS-01 demonstrated a good safety and tolerability profile and a short psychedelic experience, enabling a total in-clinic treatment of two hours.
MAPS-Logo-2021-Primary-Horizontal-White-Background-1200x486.jpg
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
PharmAla Biotech Logo 800 x 422.png
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024 18:18 ET | PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
NEW ATAI-Logo_Primary.png
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
August 07, 2024 07:00 ET | atai Life Sciences
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference in August 2024
PharmAla Biotech Logo 800 x 422.png
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
July 30, 2024 08:55 ET | PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update
22157.jpg
Psychedelic Drug (Ketamine, Psilocybin) Research Report 2024: A Global $4.6 Billion Market by 2030 - Strategic Analysis, Trends, Forecasts and Competitive Analysis 2018-2023 & 2024-2030
July 24, 2024 09:50 ET | Research and Markets
Dublin, July 24, 2024 (GLOBE NEWSWIRE) -- The "Psychedelic Drug Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...